The releaseof IL-1β is a well-established response to inflammasome activationby urate crystals.2,70,71 Thus, modulation of IL-1B levels by an MPO inhibitor would bringtherapeutic benefits, considering the role of this cytokine in thepathogenesis of gouty arthritis. This evidence concerns the gene IL1B and gout.